慢性肾脏疾病血清和尿液纤溶活性物质的改变及临床意义

目的探讨慢性肾脏疾病血清和尿液纤溶活性物质的改变及其临床意义。方法选择38例慢性肾小球肾炎(CGN),28例肾病综合征(NS),36例非透析治疗的慢性肾功能不全(CRF)和20例正常对照作为研究对象,应用ELISA法检测血清和尿液中组织型纤溶酶原激活剂(t-PA)和纤溶酶原激活物抑制剂-1(PAI-1)的浓度,同时分析尿中t-PA和PAI-1的水平与血t-PA、PAI-1、血肌酐和24h尿蛋白总量之间相关性。结果慢性肾脏疾病出现血清t-PA、PAI-1升高,尿液t-PA、PAI-1降低,其中尿液t-PA、PAI-1的改变独立于血清,不受血肌酐和24h尿蛋白定量的影响。结论慢性肾脏疾病患者存在纤溶活性物质的异常,其中尿液纤溶活性物质的改变可反应肾脏内皮细胞损伤。     

蚯蚓蛋白激酶对体内纤溶活性的增强作用研究

目的：探讨蚯蚓蛋白激酶制剂（LK）的纤溶增强作用。方法：采用静脉给药方法，观察LK对SD大鼠纤溶激活因子t-PA及其抑制物PAI-1的急性作用。结果：给药后，PAI-1活性被显著抑制（P<0.01），t-PA活性则明显增强（P<0.01）。剂量1200 U/kg体重的LK，其增强t-PA作用显著大于600U/kg体重剂量LK（P<0.05）。此外，体外观察表明:LK具有明显的激活纤溶酶原（Plg）作用，且有量-效关系，具有一定的浓度依赖性（1.56-25 kU/L）。结论：结果表明，LK具备增强纤溶的特性，静脉给药作用快速而肯定。     

Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer

Expression of urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) was evaluated in 125 surgically resected gastric cancers by immunohistochemical analysis. Tissue was stained immunohistochemically with a monoclonal antibody against human uPA and monoclonal antibodies against human PAI-1 and PAI-2. In addition, DNA ploidy patterns were determined by cytofluorometer after staining with propidium iodide. We found that 82 (66%) of the 125 gastric cancers expressed uPA as diffuse cytoplasmic staining, as intensely outlined luminal borders. PAI-1 expression was observed in 62 (50%) of 125 gastric cancer as a fine, diffuse and granular pattern in the cytoplasm. PAI-2 expression was observed in 65 (52%) of the 125 gastric cancers as a diffuse cytoplasmic staining. uPA-positive tumours showed a higher incidence of infiltration, lymph node metastasis and peritoneal dissemination than uPA-negative ones. Patients with uPA-positive tumours proved to have a significantly poorer prognosis than those with negative ones. PAI-1-negative tumours showed a higher incidence of liver metastasis and carried a poorer prognosis than PAI-1-positive ones. There was no significant correlation between uPA or PAI-1 expression and DNA ploidy patterns. Conversely, there was no significant relationship between PAI-2 expression and clinicopathological parameters and prognosis. According to the expression of uPA and PAI-1 status, groups of 19 uPA(–)/PAI-1(–), 44 uPA(+)/PAI-1(–), 23 uPA(–)/PAI-1(+) and 39 uPA(+)/PAI-1(+) were subdivided. Tumours with UPA(+)/PAI-1(–) had a significantly higher incidence of liver metastasis, lymph node metastasis and serosal invasion than the other groups of tumours. Patients with uPA(+)/PAI-1(–) tumours had a significantly poorer prognosis than those with uPA(–)/PAI-1(+) tumours. These results indicate that uPA expression is a useful biological prognostic indicator, and that uPA and PAI-1 may play an important part in the tumour progression and metastasis in gastric cancer.     

体外培养的血管内皮细胞低氧低糖损伤后tPA、PAI-1表达变化

目的：观察体外培养的血管内皮细胞低氧低糖损伤后组织型纤溶酶原激活剂(tPA)、Ⅰ型纤溶酶原激活物抑制因子(PAI-1)表达变化，探讨脑缺血后纤溶系统的变化及机制。材料和方法：制备体外内皮细胞低氧低糖损伤模型，利用HE染色、免疫细胞化学染色观察tPA、PAI-1表达变化。结果：低氧低糖损伤后，tPA、PAI-1表达均明显增强。结论：成功制备体外内皮细胞低氧低糖损伤模型。内皮细胞低氧低糖损伤可以诱导tPA、PAI-1表达增多，进一步说明脑缺血损伤后tPA、PAI-1表达增加并参与损伤过程。     

尼古丁对血管内皮细胞释放t-PA及PAI-1的影响

目的: 研究尼古丁对人脐静脉内皮细胞(HUVECs)释放组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制物-1(PAI-1)的影响。方法: HUVECs培养后接种于24孔培养板中,随机分为对照组及实验组,分别进行以下实验。(1)以0.1、1、10、100 μmol/L 尼古丁孵育HUVECs,12 h后收集各组上清液;(2)以100 μmol/L尼古丁与HUVECs孵育0、4、6、8、12 及24 h,收集各组上清液。采用ELISA法测定各组t-PA和PAI-1的浓度。结果: HUVECs与不同浓度尼古丁孵育12 h后,100 μmol/L尼古丁组PAI-1蛋白较对照组明显增加(P<0.01);0.1、1及10 μmol/L尼古丁组PAI-1蛋白与对照组比较,均无显著差异(均P>0.05);各浓度组t-PA蛋白与对照组比较,均无显著差异(均P>0.05)。HUVECs 与100 μmol/L的尼古丁分别孵育4 、6 、8 、12 及24 h,各组PAI-1蛋白均较对照组明显升高(P<0.05),且其升高呈时间依赖性;各组t-PA与对照组比较,均无显著差异(均P>0.05)。结论: 尼古丁可抑制HUVECs的纤溶活性,对内皮细胞具有损伤作用。     

睾酮对人血管内皮细胞纤溶活性影响及机制

目的：观察睾酮对人血管内皮细胞分泌纤溶酶原激活物（tPA）、纤溶酶原激活物抑制物1（PAI-1）的影响及其机制。方法： 将体外培养的人血管内皮细胞（HUVEC）分为5个浓度睾酮组及单纯培养基对照组，MTT实验观察睾酮对细胞生长及活性影响。ELISA 法测各组tPA、 PAI-1含量。用雄激素受体拮抗剂(flutamide)预处理细胞后重复实验。结果： 生理及略低于生理剂量睾酮（3×10-10 mol/L-3×10-8 mol/L）可明显促进tPA 分泌（P＜0.01）；而大剂量则使tPA 含量明显减少（P＜0.01）。各睾酮组PAI-1含量均明显低于对照组（P＜0.05）。Flutamide 能有效消除睾酮的上述作用。结论： 生理浓度睾酮通过雄激素受体促进tPA分泌，降低PAI-1浓度而增强纤溶系统活性，有利于防止血栓性疾病的发生。     

锡类散凝胶对兔输液性静脉炎治疗效果的初步观察

目的探讨锡类散凝胶对兔实验性输液性静脉炎的治疗效果及可能机制。方法将大白兔随机分为对照组、静脉炎组和锡类散治疗组，每组20只。静脉炎组在耳缘静脉注射甘露醇构建实验眭输液性静脉炎动物模型，对照组以生理盐水替代甘露醇，治疗组在造模前经锡类散预处理；在造模后相应的时间点检测兔血浆中TT（凝血酶时间）、PT（凝血酶原时间）、APTT（活化部分凝血酶时间）、PAI-1（I型纤溶酶原激活物抑制因子）和t—PA（组织型纤溶酶原激活剂）含量，并作病理学检查及评分，最后进行统计分析。结果治疗组与静脉炎组相比较（P〈0．05），能明显纠正因甘露醇而造成的高凝状态，有效降低血清t—PA水平及减轻输液静脉损害；而PAI—1含量在三组之间没有统计学差异（P〉0．05）。结论锡类散凝胶能有效改善甘露醇所致的输液胜静脉炎损害，其机制可能通过抑制血清t—PA升高而发挥治疗作用。     

Untersuchung zur Frage von persistierenden Veränderungen der Fibrinolyseparameter t-PA und PAI bei Patienten nach juvenilem ischämischen cerebralem Insult

Summary In diseases associated with thrombotic or thromboembolic complications, a reduction in the fibrinolytic potential may contribute to the risk to develop thrombosis.To investigate whether iuvenile cerebral infarction is associated with a permanent defect of the fibrinolytic system we measured the main components of the fibrinolytic system, tissue plasminogen activator (t-PA) and its fast acting inhibitor (PAI) in plasma samples of 21 patients (aged 21–44 years) 3–24 months after the acute event. The data obtained were compared to those from thirteen healthy young volunteers (22–46 years). A direct effect of known risk factors on the fibrinolytic system could be excluded because patients avoided their risk factors immediately after the ischemic cerebral attack. Hypertension and the combination of oral contraceptives and smoking had been the most striking original risk factors.Levels of t-PA antigen and t-PA activity before and after venous occlusion, or PAI activity were not different between patients and controls suggesting that at least a permanent decrease in the activity of the fibrinolytic system does not exist in these patients. However, our findings do not exclude that a temporary defect in fibrinolysis might have contributed to the acute onset of the thrombotic cerebral event possibly induced by the risk factors originally present.

---

Abkürzungen t-PA tissue plasminogen activator - PAI plasminogen activator inhibitor - RIND reversibles ischämisches neurologisches Defizit - KS kompletter Schlaganfall - TIA transitorisch ischämische Attacke     

Plasminogen Activators and Their Inhibitor in Bone Tumors and Tumor-Like Damages

Expression of urokinase- and tissue-type plasminogen activators and their inhibitor PAI-1 in the cytosolic fraction of 20 osteosarcomas, 20 chondrosarcomas, 13 giant-cell bone tumors, 5 Ewing's sarcomas, and 7 osteochondral exostoses was studied by enzyme immunoassay. The content of urokinase-type plasminogen activator increased, while the concentration of tissue-type plasminogen activator decreased in bone tumors of various histological compositions compared to osteochondral exostoses. A positive correlation was found between PAI-1 content and the volume of osteo- and chondrosarcomas. Expression of urokinase-type plasminogen activator increased in patients with primary osteosarcomas characterized by early generalization of the pathological process.     

新生大鼠缺氧缺血性脑损伤tPA、PAI-1表达的动态变化

目的:观察新生大鼠缺氧缺血性脑损伤(HIBD)中组织型纤溶酶原激活物(tPA)和1型纤溶酶原激活物抑制剂(PAI-1)表达变化的规律,探讨纤溶系统在缺氧缺血性脑损伤中的作用。方法:7日龄SD新生大鼠96只,随机分为2组:缺氧缺血性脑损伤组和假手术组。两组动物模型制备成功后3、6、12、24、36、48、72、96小时断头取脑,应用免疫组织化学及原位杂交方法检测缺氧缺血性脑损伤不同时间点t-PA、PAI-1表达的变化。结果:假手术组新生大鼠各脑区均有tPA、PAI-1蛋白及mRNA的弱表达,缺氧缺血性脑损伤组不同时间点t-PA、PAI-1二者表达呈不同的动态变化:tPA蛋白及mRNA 3小时开始表达增强,主要见于皮质和海马,神经元表达明显,血管表达较弱,48小时神经元及微血管内皮表达明显增强,72小时神经元表达明显减弱,微血管内皮见有明显阳性表达,之后表达减弱,3～96小时各时间点阳性着色神经元数目显著高于假手术组;PAI-1蛋白及mRNA 12小时表达有所增强,神经元和微血管内皮表达增多,72小时达高峰,12～96小时各时间点阳性着色神经元数目显著高于假手术组。结论:tPA和PAI-1参与HIBD的发病机制。     

Changes in the fibrinolytic system associated with physical conditioning

Summary The effects of physical conditioning on plasma fibrinolytic activity were studied in two groups of subjects. Volunteers not engaged in any sport were compared with individuals having been subjected to aerobic conditioning (middle-distance runners, defined as men running more than 80 km per week). Plasma concentrations of the different components of the fibrinolytic system were evaluated before and immediately after a maximal effort treadmill protocol. Comparison of the resting parameters revealed that under basal conditions for plasma concentrations of plasminogen, fibrinogen, 2-antiplasmin, protein C and protein S there were no differences between the two groups. Concentrations of the fibrin degradation products (FbDP) and fibrinogen degradation products (FgDP) were significantly higher in the runners than in the control group, indicating an increased fibrinolytic potential that seemed to be a consequence of the reduced formation of tissue plasminogen activator-plasminogen activator inhibitor (t-PA-PAI) complexes. Acute maximal exercise resulted in pronounced fibrinolysis, evidenced by the elevation of FbDP and FgDP concentrations, in both groups of subjects. The acceleration of the fibrinolytic activity was larger in conditioned individuals, which could be accounted for by a higher t-PA release and reduced formation of t-PA-PAI complexes when compared to the untrained subjects.     

多囊卵巢综合征患者血PAI-1和uPA含量的变化

目的观察多囊卵巢综合征(PCOS)患者外周血纤溶酶原激活抑制物1(PAI-1)和尿激酶型纤溶酶原激活物(uPA)的水平。方法实验分PCOS组和对照组,PCOS组又分为肥胖组和正常体重组,用酶联免疫吸附法(ELISA)测定PCOS组与对照组患者血浆PAI-1及血清uPA水平,并测定体重指数(BMI)、腰臀比(WHR)、空腹血糖(FPG)、空腹胰岛素及胰岛素释放试验(IRT),以稳态模型公式评估胰岛素抵抗(IR),并计算胰岛素曲线下面积(AUC)。结果PCOS组与对照组相比,黄体生成素/卵泡刺激素(LH/FSH)、睾酮(T)、空腹血糖、稳态(HOMA)指数、AUC及PAI-1含量均显著升高(P<0.05)。其中,PCOS肥胖组与正常体重组相比,HOMA指数、AUC及PAI-1含量也显著升高(P<0.05)。在相关性分析中,PAI-1与HOMA指数、PAI-1与AUC、PAI-1与BMI、HOMA-IR与BMI均有显著相关性(P<0.0001)。结论胰岛素抵抗和肥胖是影响PCOS患者PAI-1水平升高的一个很重要因素,抗PAI-1的研究可能为多囊卵巢综合征的治疗提供一个新的方法。     

儿童脓毒症纤溶酶原激活物抑制剂-1基因启动子区4G/5G多态性的研究

目的探讨纤溶酶原激活物抑制剂-1（PAI-1）基因启动子区单核苷酸插入或缺失（4G/5G）多态性与广州地区汉族脓毒症患儿的相关性,对脓毒症的发生、发展和临床预后的影响。方法选取2007年4-12月广州市妇女儿童医疗中心诊治的汉族脓毒症患儿为病例组,同期收集健康查体儿童为对照组。应用等位基因特异性扩增多聚酶链（AS-PCR）法对病例组和对照组行PAI-1基因启动子区4G/5G多态性检测和分析。采用基因计数法计算各组基因型频率和等位基因频率,χ^2检验分析比较两组人群各基因型的分布差异,计算OR值及其95%CI评估各基因型的风险。结果研究期间病例组纳入148例,对照组181名。病例组和对照组PAI-1基因启动子区4G/5G多态性的基因型和等位基因频率分布差异无统计学意义（χ^2=0.79,P〉0.05）。等位基因4G（χ^2=4.35,P〈0.05）及其纯合子（χ^2=4.44,P〈0.05）与脓毒症发展相关;携带等位基因4G患儿发展至重症脓毒症的风险比5G高,OR=4.05（95%CI：1.09-15.08）,4G/4G纯合子患儿发展至重症脓毒症的风险比其他基因型高,OR=4.57（95%CI：1.11-18.78）。等位基因4G（χ^2=9.17,P〈0.05）及其纯合子（χ^2=7.35,P〈0.05）与脓毒症病死率相关,携带等位基因4G患儿脓毒症病死风险较5G高,OR=4.30（95%CI：1.50-12.29）,4G/4G纯合子患儿脓毒症病死风险较其他基因型高,OR=3.14（95%CI：1.49-6.61）。结论PAI-1基因启动子区4G/5G多态性与广州地区汉族脓毒症患儿进展及预后相关,等位基因4G及其纯合子是其高危遗传因素;PAI-1基因启动子区4G/5G点多态性与脓毒症的易感性无关。     

Tissue- and Urokinase-Type Plasminogen Activators and Type 1 Plasminogen Activator Inhibitor in Melanomas and Benign Skin Pigment Neoplasms

The content of urokinase- and tissue-type plasminogen activators and plasminogen activator inhibitor PAI-1 in the cytosol of primary and metastatic melanomas and benign skin pigment neoplasms was estimated by enzyme immunoassay. It was shown that local growth and invasion of melanomas are related to suppressed expression of tissue plasminogen activator. The content of urokinase plasminogen activator increases in patients with distant metastases and large thickness of the primary tumor.     

凝血和纤溶失衡在急性肺损伤中的作用

急性肺损伤(acute lung injury,ALI),以肺泡上皮细胞和血管内皮屏障损伤、急性炎症反应、富含蛋白的肺水肿为特征,是一种临床常见的危重病症,可进一步发展为急性呼吸窘迫综合症(acute respiratory distress syndrome,ARDS).     

The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma

BackgroundThe urokinase-type plasminogen activator (uPA) system is closely related to the occurrence and progression of cancer in many aspects. Previous studies demonstrated that the conclusions about the prognosis value of uPA, plasminogen activator inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2) in lung cancer are controversial, so this study was performed for the exploration of the predictive effect of uPA, PAI-1 and PAI-2 on the overall survival (OS) of resectable pulmonary adenocarcinoma patients.MethodsUPA, PAI-1 and PAI-2 expression levels were assayed by immunohistochemical staining based on tissue microarray (TMA) that is composed of formalin-fixed paraffin-embedded specimens from 84 resectable lung adenocarcinoma patients from July 2004 to June 2009. The relationship of IHC, mRNA expression levels of three molecules were investigated respectively. The three molecules’ relationship with clinicopathologic parameters and OS was explored by Chi-square, Kaplan-Meier, and Cox regression analyses. The Cancer Genome Atlas (TCGA) database was used to analyze differential gene expressions of RNA-sequencing data of pulmonary adenocarcinoma and normal tissues, and Kaplan-Meier methods were adopted to confirm the prognostic value of uPA, PAI-1 and PAI-2 in resectable lung adenocarcinoma in TCGA database and the R package MethylMix was used to conduct an analysis integrating methylation data and gene expression of RNA-sequencing data based on TCGA.ResultsUPA, PAI-1 and PAI-2 had much higher IHC expression levels in tumor than those in the normal tissues (uPA, Z = -10.511; PAI-1, Z = -4.836; PAI-2, Z = -6.794; all P < 0.0001). High DNA methylation level of gene uPA resulted in the decrease of its expression. In addition, expression level of PAI-2 was positively associated with tumor size (χ² = 8.372, P = 0.004). Multivariate analyses showed TNM stage III was an independent adverse prognostic factor (hazard ratio = 3.736, 95 % confidence interval = 1.097–12.72, P = 0.035). Kaplan-Meier method revealed that uPA, PAI-1 and PAI-2 expression levels were not related to the OS for 84 resectable lung adenocarcinoma patients. According to TCGA data, PAI-1 expression level was identified as a potential adverse predictor for prognosis of resectable lung adenocarcinoma (Gehan-Breslow-Wilcoxon test, P = 0.025).ConclusionsOur data show that, the expression levels of uPA, PAI-1 and PAI-2 are significantly up-regulated in resectable lung adenocarcinoma. Besides, this study highlights PAI-1 as a latent adverse prognostic factor in resectable adenocarcinoma of lung.     

蚓激酶（普恩复）治疗脑梗塞时抗凝和纤溶变化的临床研究

目的：探讨蚓激酶（普恩复）治疗急性脑梗塞时抗凝和纤溶的变化。方法：随机选择31例脑梗塞例患者，服药前后对患者行神经功能缺失评分、血浆中KPTT、PT、FIB、t－PA、PAI、D－二聚体的测定，并与以丹参治疗的20例脑梗塞患者进行对照。结果：患者口服蚓激酶后（400mg，3次／日），KPTT明显延长（P＜0．05），FIB明显减少（P＜0．05），t－PA活性明显增强（P＜0．01），D－二聚体明显增加（P＜0．01），以上指标在对照组中治疗前后无明显变化（P＞0．05）。治疗组、对照组PT、PAI在用药前后均无明显变化（P＞0．05）。结论：蚓激酶治疗脑梗塞取得疗效与内凝血途径抑制、纤溶的激活有关。     

血浆同型半胱氨酸对糖尿病肾脏损伤机制的探讨

目的探讨血浆同型半胱氨酸水平与糖尿病肾脏病大鼠肾组织表达PAI-1的关系,并探讨其引起肾损伤可能的机制。方法38只健康SD雄性大鼠随机分为正常对照组及糖尿病组。用链佐菌素（STZ）诱导糖尿病大鼠模型,于第4、8、12周末收集24h尿测定UAER,并处死大鼠,心脏采血,ELISA法测血浆同型半胱氨酸（Hcy）水平,生化分析仪测血糖、血肌酐等生化指标。取肾脏称重,免疫组织化学法测肾组织中PAI-1的表达情况。结果与正常对照组相比,①糖尿病组大鼠肾肥大指数（肾质量/体质量,KW/BW）、UAER显著增加（P〈0.05）;②糖尿病组大鼠血浆Hcy浓度明显升高（P〈0.01）,且随病程延长而逐渐增加,肾组织表达PAI-1明显增强（P〈0.05）;③相关分析表明,血浆Hcy水平与肾组织表达PAI-1强度及UAER呈显著正相关（r=0.641,r=0.684,P〈0.01）。结论血浆Hcy参与了糖尿病肾损伤的发生、发展,其机制可能与其造成内皮损伤,引起纤溶系统失衡等因素有关。     

辛伐他汀对尼古丁诱导脐静脉 内皮细胞分泌t-PA和PAI-1的影响

目的: 研究不同浓度辛伐他汀对尼古丁诱导人脐静脉内皮细胞(HUVECs)分泌组织纤溶酶原激活物(t-PA)和1型纤溶酶原激活物抑制剂(PAI-1)及其基因表达的影响。方法: 将3-6代体外培养的HUVECs随机分为对照组、尼古丁组及不同浓度辛伐他汀组,辛伐他汀组分别以1、10、100 μmol/L辛伐他汀预处理细胞2 h,再以100 μmol/L尼古丁孵育24 h。酶联免疫吸附双抗体夹心法(ELISA)检测细胞上清液t-PA和PAI-1含量;逆转录聚合酶链反应(RT-PCR)检测细胞t-PA和PAI-1 mRNA的表达。结果: 尼古丁组PAI-1分泌和mRNA表达较对照组显著升高(P<0.05)。不同浓度辛伐他汀组PAI-1分泌和mRNA表达均较尼古丁组显著降低,且PAI-1分泌和mRNA表达的降低呈浓度依赖性(均P<0.05),以100 μmol/L辛伐他汀组最为显著。100 μmol/L辛伐他汀组PAI-1分泌和mRNA表达与对照组比较,无显著差异(P>0.05)。尼古丁组t-PA mRNA表达较对照组显著降低(P<0.05)。10、100 μmol/L辛伐他汀组t-PA mRNA表达较尼古丁组显著升高(P<0.05),各组间t-PA分泌无显著差异(均P>0.05)。结论: 在体外,辛伐他汀可降低尼古丁所致的PAI-1分泌和mRNA的表达,并升高t-PA mRNA的表达,从而逆转尼古丁介导的HUVECs纤溶活性减低。     

Effects of supplemental perioperative oxygen on post-operative abdominal wound adhesions in a mouse laparotomy model with controlled respiratory support

BACKGROUND: Post-operative adhesion formation is a major clinical problem. Tissue oxygenation is one of the most important determinants in adhesion formation. The objective of this study was to investigate whether supplemental perioperative oxygen could reduce post-operative adhesion formation through increasing the peritoneal tissue oxygen tension (PitO(2)) in a mouse model. METHODS: Adult C57BJ6 mice were randomly assigned to two groups: Group 1 (n = 20), Fraction of Inspired Oxygen (FiO(2)): 0.21; Group 2 (n = 20), FiO(2): 0.80. On day 0, over the course of the 90 min procedure including the 60 min of laparotomy, PitO(2) was continuously monitored. On day 7, a second laparotomy was performed to assess abdominal wound adhesions. Real-time RT-PCR was performed to measure expression levels of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) mRNA in peritoneal tissues. RESULTS: The PitO(2) levels in Group 2 were significantly higher compared to Group 1 (P < 0.001) and controls (P < 0.003). There was no significant difference in the incidence of abdominal wound adhesions; however, the severity of adhesions was significantly reduced in Group 2 compared to Group 1 (P < 0.03). A significantly higher tPA/PAI-1 mRNA ratio was detected in Group 2 and the controls compared to Group 1 (P < 0.02 and P < 0.002, respectively). CONCLUSIONS: Supplemental perioperative oxygen may help to reduce post-operative adhesion formation.